157 related articles for article (PubMed ID: 36128637)
1. Thymus and activation-regulated chemokine (TARC) as treatment response marker for paediatric Hodgkin lymphoma: A pilot study.
Zijtregtop EAM; Diez C; Zwaan CM; Veening MA; Beishuizen A; Meyer-Wentrup FAG
Br J Haematol; 2023 Jan; 200(1):70-78. PubMed ID: 36128637
[TBL] [Abstract][Full Text] [Related]
2. Plasma thymus and activation-regulated chemokine (TARC) as diagnostic marker in pediatric Hodgkin lymphoma.
Zijtregtop EAM; Meyer-Wentrup F; Wong WC; Hoogendijk R; Lopez-Yurda M; Zwaan CM; Beishuizen A
EJHaem; 2020 Jul; 1(1):152-160. PubMed ID: 35847691
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study.
Hsi ED; Li H; Nixon AB; Schöder H; Bartlett NL; LeBlanc M; Smith S; Kahl BS; Leonard JP; Evens AM; Scott DW; Rimsza LM; Friedberg JW
Blood; 2019 Apr; 133(16):1762-1765. PubMed ID: 30723079
[TBL] [Abstract][Full Text] [Related]
4. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.
Farina L; Rezzonico F; Spina F; Dodero A; Mazzocchi A; Crippa F; Alessi A; Dalto S; Viviani S; Corradini P
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1982-8. PubMed ID: 25240818
[TBL] [Abstract][Full Text] [Related]
5. CD68+ cell count, early evaluation with PET and plasma TARC levels predict response in Hodgkin lymphoma.
Cuccaro A; Annunziata S; Cupelli E; Martini M; Calcagni ML; Rufini V; Giachelia M; Bartolomei F; Galli E; D'Alò F; Voso MT; Leone G; Giordano A; Larocca LM; Hohaus S
Cancer Med; 2016 Mar; 5(3):398-406. PubMed ID: 26758564
[TBL] [Abstract][Full Text] [Related]
6. Early serum TARC reduction predicts prognosis in advanced-stage Hodgkin lymphoma patients treated with a PET-adapted strategy.
Viviani S; Mazzocchi A; Pavoni C; Taverna F; Rossi A; Patti C; Romano A; Trentin L; Sorasio R; Guidetti A; Gottardi D; Tarella C; Cimminiello M; Zanotti R; Farina L; Ferreri AJM; Galbiati M; Corradini P; Gianni AM; Gallamini A; Rambaldi A
Hematol Oncol; 2020 Oct; 38(4):501-508. PubMed ID: 32602970
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC.
Plattel WJ; Alsada ZN; van Imhoff GW; Diepstra A; van den Berg A; Visser L
Br J Haematol; 2016 Dec; 175(5):868-875. PubMed ID: 27610595
[TBL] [Abstract][Full Text] [Related]
8. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
9. Biology and Clinical Applicability of Plasma Thymus and Activation-Regulated Chemokine (TARC) in Classical Hodgkin Lymphoma.
Zijtregtop EAM; van der Strate I; Beishuizen A; Zwaan CM; Scheijde-Vermeulen MA; Brandsma AM; Meyer-Wentrup F
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33672548
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor.
Weihrauch MR; Manzke O; Beyer M; Haverkamp H; Diehl V; Bohlen H; Wolf J; Schultze JL
Cancer Res; 2005 Jul; 65(13):5516-9. PubMed ID: 15994922
[TBL] [Abstract][Full Text] [Related]
11. The value of thymus and activation related chemokine immunohistochemistry in classic Hodgkin lymphoma diagnostics.
Kilsdonk M; Veldman C; Rosati S; Plattel W; Diepstra A
Histopathology; 2023 Feb; 82(3):495-503. PubMed ID: 36345263
[TBL] [Abstract][Full Text] [Related]
12. Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma.
Plattel WJ; van den Berg A; Visser L; van der Graaf AM; Pruim J; Vos H; Hepkema B; Diepstra A; van Imhoff GW
Haematologica; 2012 Mar; 97(3):410-5. PubMed ID: 22058214
[TBL] [Abstract][Full Text] [Related]
13. Early reduction of serum TARC levels may predict for success of ABVD as frontline treatment in patients with Hodgkin Lymphoma.
Guidetti A; Mazzocchi A; Miceli R; Paterno' E; Taverna F; Spina F; Crippa F; Farina L; Corradini P; Gianni AM; Viviani S
Leuk Res; 2017 Nov; 62():91-97. PubMed ID: 28992524
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of Eight Immunohistochemical Markers Expressed in the Tumor Microenvironment and on Hodgkin Reed-Sternberg Cells in Pediatric Patients With Classical Hodgkin Lymphoma.
Zijtregtop EAM; Tromp I; Dandis R; Zwaan CM; Lam KH; Meyer-Wentrup FAG; Beishuizen A
Pathol Oncol Res; 2022; 28():1610482. PubMed ID: 36032657
[TBL] [Abstract][Full Text] [Related]
15. Development of an Electrochemical CCL17/TARC Biosensor toward Rapid Triage and Monitoring of Classic Hodgkin Lymphoma.
Rinaldi C; Corrigan DK; Dennany L; Jarrett RF; Lake A; Baker MJ
ACS Sens; 2021 Sep; 6(9):3262-3272. PubMed ID: 34478275
[TBL] [Abstract][Full Text] [Related]
16. Interim thymus and activation regulated chemokine versus interim
Plattel WJ; Visser L; Diepstra A; Glaudemans AWJM; Nijland M; van Meerten T; Kluin-Nelemans HC; van Imhoff GW; van den Berg A
Br J Haematol; 2020 Jul; 190(1):40-44. PubMed ID: 32106342
[TBL] [Abstract][Full Text] [Related]
17. TARC, a CC chemokine, is frequently expressed in classic Hodgkin's lymphoma but not in NLP Hodgkin's lymphoma, T-cell-rich B-cell lymphoma, and most cases of anaplastic large cell lymphoma.
Peh SC; Kim LH; Poppema S
Am J Surg Pathol; 2001 Jul; 25(7):925-9. PubMed ID: 11420464
[TBL] [Abstract][Full Text] [Related]
18. The biological environment of Hodgkin's lymphoma and the role of the chemokine CCL17/TARC.
Hnátková M; Mociková H; Trnený M; Zivný J
Prague Med Rep; 2009; 110(1):35-41. PubMed ID: 19591376
[TBL] [Abstract][Full Text] [Related]
19. Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant.
Harrison SJ; Hsu AK; Neeson P; Younes A; Sureda A; Engert A; Prince HM; Li M; Savage P; Bugarini R; Williams D; Squier M; Ritchie DS
Leuk Lymphoma; 2014 May; 55(5):1053-60. PubMed ID: 23822537
[TBL] [Abstract][Full Text] [Related]
20. Serum CD163 and TARC as disease response biomarkers in classical Hodgkin lymphoma.
Jones K; Vari F; Keane C; Crooks P; Nourse JP; Seymour LA; Gottlieb D; Ritchie D; Gill D; Gandhi MK
Clin Cancer Res; 2013 Feb; 19(3):731-42. PubMed ID: 23224400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
